Literature DB >> 29325706

Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos).

Maxime Palazzo1, Bertrand Napoléon2, Rodica Gincul2, Mathieu Pioche3, Bertrand Pujol2, Christine Lefort2, Fabien Fumex2, Vincent Hautefeuille4, Monique Fabre5, Jérome Cros6, Michèle Felce6, Anne Couvelard7, Alain Sauvanet8, Philippe Lévy9, Philippe Ruszniewski9, Laurent Palazzo10.   

Abstract

BACKGROUND AND AIMS: Contrast harmonic EUS (CH-EUS) has the ability to depict tumor microvasculature. Decreased microvascular density has been identified as a factor associated with tumor aggressiveness. We aimed to study the accuracy of CH-EUS for the prediction of pancreatic neuroendocrine tumor (PNET) aggressiveness.
METHODS: Between June 2009 and March 2015, all consecutive patients with histology-proven PNETs and CH-EUS examination were included. Nine endosonographers blindly analyzed all videos. CH-EUS tumor aggressiveness was defined as a heterogeneous enhancement at the early arterial phase. The final diagnosis of tumor aggressiveness was defined as follows: G3 tumors, morphologic and/or histologic findings of metastatic disease in G1/G2 tumors. Diagnostic values were calculated. Intratumoral microvascular density and fibrosis were assessed on pathologic specimens.
RESULTS: Eighty-one tumors were included, of which 26 were aggressive (32.1%). In CH-EUS 35 tumors (43.2%) had a heterogeneous enhancement. The overall accuracy, sensitivity, specificity, positive predictive value, and negative predictive value of CH-EUS for the diagnosis of tumor aggressiveness were 86%, 96%, 82%, 71%, and 98%, respectively. The interobserver agreement among the 9 endosonographers was good (k = .66). The intraobserver agreement was excellent for the junior (κ = .83) and senior (κ = .82) endosonographers. Heterogeneous tumors at CH-EUS corresponded to fewer vascular and more fibrotic tumors (P < .01).
CONCLUSIONS: CH-EUS is accurate in the prediction of PNET aggressiveness and could be a decision-making element in their management.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29325706     DOI: 10.1016/j.gie.2017.12.033

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  5 in total

1.  Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis.

Authors:  Ke Chen; Wenming Zhang; Zhaozhen Zhang; Yiping He; Yuan Liu; Xiujiang Yang
Journal:  Dig Dis Sci       Date:  2018-08-18       Impact factor: 3.199

Review 2.  Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Andrew Canakis; Linda S Lee
Journal:  World J Gastrointest Endosc       Date:  2022-05-16

3.  Contrast-enhanced harmonic endoscopic ultrasound using time-intensity curve analysis predicts pathological grade of pancreatic neuroendocrine neoplasm.

Authors:  Saimon Takada; Hironari Kato; Yosuke Saragai; Shinichiro Muro; Daisuke Uchida; Takeshi Tomoda; Kazuyuki Matsumoto; Shigeru Horiguchi; Noriyuki Tanaka; Hiroyuki Okada
Journal:  J Med Ultrason (2001)       Date:  2019-08-03       Impact factor: 1.314

4.  Calcitonin-negative neuroendocrine tumor of the thyroid with metastasis to liver-rare presentation of an unusual tumor: A case report and review of literature.

Authors:  Huai-Jie Cai; Han Wang; Nan Cao; Bin Huang; Fan-Lei Kong; Li-Ren Lu; Ya-Yuan Huang; Wei Wang
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

Review 5.  Diagnosis, treatment, and current concepts in the endoscopic management of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Giuseppe Iabichino; Milena Di Leo; Monica Arena; Giovanni Giuseppe Rubis Passoni; Elisabetta Morandi; Francesca Turpini; Paolo Viaggi; Carmelo Luigiano; Luca De Luca
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.